4.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.12
Aprire:
$4.12
Volume 24 ore:
208.57K
Relative Volume:
0.72
Capitalizzazione di mercato:
$166.57M
Reddito:
$2.00M
Utile/perdita netta:
$109.16M
Rapporto P/E:
1.5754
EPS:
2.5835
Flusso di cassa netto:
$-9.11M
1 W Prestazione:
+0.99%
1M Prestazione:
-15.38%
6M Prestazione:
+20.77%
1 anno Prestazione:
+89.30%
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Nome
Oramed Pharmaceuticals Inc
Settore
Industria
Telefono
646-844-1164
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ORMP
Oramed Pharmaceuticals Inc
|
4.07 | 170.25M | 2.00M | 109.16M | -9.11M | 2.5835 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-09 | Iniziato | National Securities | Buy |
| 2020-12-03 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-11 | Iniziato | Aegis Capital | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-12-11 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Reiterato | FBR Capital | Outperform |
| 2015-12-01 | Reiterato | H.C. Wainwright | Buy |
| 2015-11-19 | Iniziato | FBR Capital | Outperform |
| 2015-04-13 | Ripresa | MLV & Co | Buy |
| 2014-01-30 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Iniziato | MLV & Co | Buy |
| 2013-12-03 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Oramed Pharmaceuticals Inc Borsa (ORMP) Ultime notizie
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Cash Flow - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Balance Sheet - TradingKey
Oramed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:ORMP - TradingView
TradingKey - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oramed Pharmaceuticals Inc (OJU1.SG) stock price, news, quote and history - Yahoo Finance UK
AlTi Global Leads Our Selection Of 3 Promising Penny Stocks - simplywall.st
Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback - Ad-hoc-news.de
Oramed Pharmaceuticals Inc. Net Worth (2026) - GuruFocus
Price to sales forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects - Ad-hoc-news.de
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet - AOL.com
Oramed Pharmaceuticals outlines its oral drug strategy as Nasdaq-listed biotech pursues long-term gr - Ad Hoc News
Price to earnings forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Price to book forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals stock holds its ground. Investors await the next company update. - ad-hoc-news.de
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
Insider Sell: Avraham Gabay Sells 73,360 Shares of Oramed Pharma - GuruFocus
Oramed Pharmaceuticals COO & Cbo Sold Shares Worth Over $611K - TradingView
Oramed (NASDAQ: ORMP) COO sells 137K shares after option exercise - Stock Titan
ORAMED (NASDAQ: ORMP) CFO executes pre-planned sale of 73,360 shares - Stock Titan
Oramed Pharmaceuticals Incorporated Financial Disclosures & SEC Filings - TradingView
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 July By Investing.com - Investing.com South Africa
137,000 shares flagged for sale by Oramed (NASDAQ: ORMP) in Form 144 - Stock Titan
Oramed (NASDAQ: ORMP) Form 144 notes 93,360 RSU shares on 06/18/2026 - Stock Titan
Oramed Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Oramed Pharm Updates Bylaws, Streamlining Shareholder Actions - TipRanks
Oramed (NASDAQ: ORMP) revises bylaws and restructures Scilex note obligations - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2000 Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2000 Value Benchmark - marketscreener.com
BML Investment Holds 2.5% of Oramed (ORMP) in Amended 13G/A - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 3000E Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 2000 Value-Defensive Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2500 Value Benchmark - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 3000E Value Benchmark - marketscreener.com
Oramed Pharmaceuticals Incorporated Actuals & Estimates (MUN:OJU1) - TradingView
Oramed Pharmaceuticals Incorporated Actuals & Estimates (DUS:OJU1) - TradingView
These healthcare stocks are combining strong gains with reasonable prices - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Oramed Releases Letter to Shareholders, Highlighting Russell 200 - GuruFocus
Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP) - TradingView
Oramed's Pivot Pays Off: From Pharma Hopeful to Investment Powerhouse - BriefGlance
ORMP SEC FilingsOramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Daily Brief United States: Tesla , Adobe Systems, Nine Energy Service , Oramed Pharmaceuticals , Olin Corp, Earth Science Tech, Kardigan, Generac Holdings, General Motors, Nucor Corp and more - Smartkarma
ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community - Yahoo Finance
Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oramed Pharmaceuticals Inc Azioni (ORMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oramed Pharmaceuticals Inc Azioni (ORMP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hexter Joshua | COO & CBO |
Jul 01 '26 |
Sale |
4.46 |
137,000 |
611,431 |
1,023,384 |
| Gabay Avraham | Chief Financial Officer |
Jul 01 '26 |
Sale |
4.51 |
73,360 |
330,744 |
671,785 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):